Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

Patients treated for DLBCL are at high risk of developing AICD. This adverse event is characterized by irreversible damage to the heart muscle with a loss of cardiomyocytes and subsequent decline in cardiac pumping capacity. Thereby patients treated for this malignancy are at double the risk of developing symptomatic heart failure / cardiomyopathy when compared to the general population. This corresponds to a cumulative incidence of 5-10% within 5-years after receiving R-CHOP. In the elderly, an incidence of 26% has been reported after 8-years of follow-up. Among patients who die in complete r

Trial Details

NCT ID

NCT06220032

Phase

PHASE3

Sponsor

Stichting Hemato-Oncologie voor Volwassenen Nederland

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Dexrazoxane
Rituximab
Cyclophosphamide
Doxorubicin
Vincristine
Prednisolone

Locations (sample)

's-Hertogenbosch, Netherlands|51.69917,5.30417
Almelo, Netherlands|52.35667,6.6625
Amstelveen, Netherlands|52.30083,4.86389
Apeldoorn, Netherlands|52.21,5.96944
Arnhem, Netherlands|51.98,5.91111

Key Eligibility Criteria

Untreated patients with a confirmed histologic diagnosis of CD20+ DLBCL according to WHO classification 2022:
DLBCL, not otherwise specified (NOS)
High-grade B-cell lymphoma NOS
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocation when DA-EPOCH-R is not an option. R2- CHOP is allowed.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →